Subscribe
shutterstock_1905552877_nitpicker
nitpicker / Shutterstock.com
5 April 2022EuropeMuireann Bolger

Pharma patent filings rise at EPO amid pandemic

Patent applications in Europe reached record levels during 2021 amid the COVID-19 pandemic, according to a new report by the European Patent Office (EPO).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Compugen’s anti-PVRIG patent upheld by the EPO
18 July 2023   Opposition Division ruling supports the use of immunotherapy patent | Highlights the significance of plausibility in patent evaluation following G 2/21.
Europe
EPO Enlarged Board of Appeal issues G 2/21 decision
28 March 2023   Board provides guidance on evidence submitted after patent filing date | Eagerly awaited decision confirms what’s needed to prove a certain effect.
Big Pharma
Biopharma group urges fairer access to pandemic protection
21 July 2022   Global industry body launches declaration | Poorer nations could benefit from more equitable vaccine access | Proposal to be tabled among G7 and G20.


Editor's picks

‘We created law’: G1/24 and the creation of the ‘diamond standard’
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

Editor's picks

Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Biotechnology
Compugen’s anti-PVRIG patent upheld by the EPO
18 July 2023   Opposition Division ruling supports the use of immunotherapy patent | Highlights the significance of plausibility in patent evaluation following G 2/21.
Europe
EPO Enlarged Board of Appeal issues G 2/21 decision
28 March 2023   Board provides guidance on evidence submitted after patent filing date | Eagerly awaited decision confirms what’s needed to prove a certain effect.
Big Pharma
Biopharma group urges fairer access to pandemic protection
21 July 2022   Global industry body launches declaration | Poorer nations could benefit from more equitable vaccine access | Proposal to be tabled among G7 and G20.

More on this story

Biotechnology
Compugen’s anti-PVRIG patent upheld by the EPO
18 July 2023   Opposition Division ruling supports the use of immunotherapy patent | Highlights the significance of plausibility in patent evaluation following G 2/21.
Europe
EPO Enlarged Board of Appeal issues G 2/21 decision
28 March 2023   Board provides guidance on evidence submitted after patent filing date | Eagerly awaited decision confirms what’s needed to prove a certain effect.
Big Pharma
Biopharma group urges fairer access to pandemic protection
21 July 2022   Global industry body launches declaration | Poorer nations could benefit from more equitable vaccine access | Proposal to be tabled among G7 and G20.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?